Differential Diagnosis of Rare Skin Conditions

In phase 3 INTREPID, lutikizumab beat placebo on HiSCR75 at week 16 and met all 8 ranked secondary end points in moderate to severe HS.

Todd Schlesinger, MD, discusses Ameluz PDT for sBCC, adjuvant cemiplimab, remibrutinib for symptomatic dermographism, and nonsurgical skin cancer care.

Stephan Weidinger, MD, PhD, discusses 5-year ADlong data showing durable skin clearance and itch control with lebrikizumab in atopic dermatitis.

Oral bitopertin met all primary and secondary endpoints in the phase 3 APOLLO trial in EPP, cutting PPIX and increasing pain-free time in light.